You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Details for Patent: 10,570,139


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,570,139 protect, and when does it expire?

Patent 10,570,139 protects BRUKINSA and is included in one NDA.

This patent has thirty-four patent family members in twenty-seven countries.

Summary for Patent: 10,570,139
Title:Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001##
Inventor(s): Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN)
Assignee: BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:15/969,864
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,570,139

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the intellectual property landscape effectively. This article delves into the details of United States Patent 10,570,139, focusing on its claims, scope, and the broader patent landscape.

Patent Overview

US10570139B2: Substituted Pyrazolo[1,5-a]pyrimidines as Bruton's Tyrosine Kinase Modulators

This patent, issued to inventors working on pharmaceutical compounds, discloses certain fused heterocyclic compounds useful for inhibiting protein kinase, specifically Bruton's tyrosine kinase (Btk). Btk is a key enzyme in the B-cell receptor signaling pathway and is a target for treating various diseases, including certain types of leukemia and autoimmune disorders[4].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the broadest aspects of the invention and are critical in determining the patent's boundaries.

  • Claim 1: This claim often sets the foundation by describing the general structure of the substituted pyrazolo[1,5-a]pyrimidines.
  • Claim 2-5: These claims may narrow down the scope by specifying particular substituents, functional groups, or other structural elements.

Dependent Claims

Dependent claims build upon the independent claims, providing more specific details about the invention. These claims can include variations in the chemical structure, synthesis methods, or specific applications of the compounds.

  • Claim 6-10: These might include specific examples of compounds, their synthesis routes, or their use in pharmaceutical compositions.

Scope of the Invention

The scope of the patent is defined by the claims and the description provided in the specification. Here are some key aspects:

Chemical Structure

The patent describes a class of fused heterocyclic compounds, specifically substituted pyrazolo[1,5-a]pyrimidines. The chemical structure is detailed, including the presence of specific functional groups and substituents that are crucial for the biological activity of these compounds[4].

Biological Activity

The compounds are disclosed as modulators of Bruton's tyrosine kinase, which implies their potential use in treating diseases associated with Btk activity. This biological activity is a critical aspect of the patent's scope.

Pharmaceutical Applications

The patent also covers the use of these compounds in pharmaceutical compositions. This includes formulations, dosages, and methods of administration, which are essential for their practical application in medicine.

Patent Landscape

Prior Art

To understand the novelty and non-obviousness of the invention, it is essential to review the prior art cited in the patent. The prior art keywords, such as "phenoxyphenyl," "carboxamide," and "pyrimidine," indicate the existing knowledge in the field that the inventors built upon[4].

International Patent Family

Using tools like the Global Dossier provided by the USPTO, one can identify related applications filed at participating IP Offices. This helps in understanding the global protection and the family of patents related to this invention[1].

Citation Data

The Common Citation Document (CCD) application can provide a consolidated view of the prior art cited by all participating offices for the family members of this patent application. This is useful for assessing the patent's strength and potential challenges[1].

Search and Analysis Tools

USPTO Resources

  • Patent Public Search: This tool can be used to search for similar patents and published patent applications to understand the broader patent landscape.
  • Global Dossier: This service provides access to the file histories of related applications from participating IP Offices, helping to identify the patent family and citation data.
  • Patent and Trademark Resource Centers (PTRCs): These centers offer local search resources and training in patent search techniques, which can be invaluable for detailed analysis[1].

International Databases

Databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) can be used to search for international patents and understand the global scope of similar inventions[1].

Economic and Legal Considerations

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide insights into the trends and measurements of patent scope. This dataset includes detailed information on claims from U.S. patents and can help in understanding the scope and claims of similar patents[3].

Small Claims Patent Court

For disputes related to patent infringement or validity, the concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), could provide a more accessible and cost-effective legal framework[2].

Key Takeaways

  • Claims and Scope: The patent's claims define its scope, including the chemical structure, biological activity, and pharmaceutical applications.
  • Prior Art and Citation Data: Understanding prior art and citation data is crucial for assessing the novelty and non-obviousness of the invention.
  • Global Patent Family: Using tools like Global Dossier and CCD helps in identifying related applications and understanding global protection.
  • Search and Analysis Tools: Utilizing USPTO resources and international databases is essential for a comprehensive analysis.
  • Economic and Legal Considerations: Understanding patent scope measurements and legal frameworks can help in navigating disputes and economic implications.

FAQs

Q: What is the main subject of United States Patent 10,570,139? A: The patent discloses substituted pyrazolo[1,5-a]pyrimidines as modulators of Bruton's tyrosine kinase.

Q: How can I search for similar patents? A: You can use the USPTO's Patent Public Search tool, Global Dossier, and international databases like those from the EPO and WIPO.

Q: What is the significance of prior art in patent analysis? A: Prior art helps in assessing the novelty and non-obviousness of the invention by comparing it to existing knowledge in the field.

Q: How can I understand the global protection of a patent? A: Using the Global Dossier and Common Citation Document (CCD) can help in identifying related applications and understanding global protection.

Q: What resources are available for training in patent search techniques? A: The USPTO's Patent and Trademark Resource Centers (PTRCs) offer local search resources and training in patent search techniques.

Sources

  1. USPTO - Search for patents.
  2. ACUS - U.S. Patent Small Claims Court.
  3. USPTO - Patent Claims Research Dataset.
  4. Google Patents - US10570139B2.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,570,139

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Beigene BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA ⤷  Try for Free
Beigene BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Try for Free
Beigene BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) ⤷  Try for Free
Beigene BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try for Free
Beigene BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,570,139

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/CN2013/074728Apr 25, 2013

International Family Members for US Patent 10,570,139

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2989106 ⤷  Try for Free 301161 Netherlands ⤷  Try for Free
European Patent Office 2989106 ⤷  Try for Free PA2022504 Lithuania ⤷  Try for Free
European Patent Office 2989106 ⤷  Try for Free LUC00250 Luxembourg ⤷  Try for Free
European Patent Office 2989106 ⤷  Try for Free CA 2022 00008 Denmark ⤷  Try for Free
European Patent Office 2989106 ⤷  Try for Free 122022000013 Germany ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.